Latest Vascular endothelial growth factor Stories
TARRYTOWN, N.Y., Feb. 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
In patients with moderate or worse vision loss at baseline, those treated with EYLEA gained, on average, an additional full line or more on an eye chart when compared to those treated with alternative
SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015 /PRNewswire/ -- Pfenex Inc.
CRESTWOOD, Ky., Feb. 10, 2015 /PRNewswire/ -- Apellis Pharmaceuticals, Inc.
Blindness rates for common eye disease falling; macular degeneration treatments better than ever SAN FRANCISCO, Feb.
New Insights, Discoveries and Interim Clinical Data on Generx® Phase 3 Angiogenic Therapy for Patients with Cardiac Microvascular Insufficiency and Coronary Artery Disease SAN DIEGO,
TARRYTOWN, N.Y., Jan. 23, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
-- DIG-KT is a novel bi-specific mAb targeting VEGFR2 and Tie-2 pathways for treating cancers SHENYANG, China and DAEJEON, South Korea, Jan. 14, 2015 /PRNewswire/ -- 3SBio Inc.
DALLAS, December 15, 2014 /PRNewswire/ -- ReportsnReports.com adds Ocular Disorders: Rising Therapeutics, Technologies, and Devices 2014 market research report that covers
With Americans spending billions of dollars each year on nutritional supplements, researchers have analyzed popular eye vitamins to determine whether their formulations and claims are consistent with scientific findings.
- A political dynamiter.